Dr. Amy Pomeroy (@AmyEPomeroy) profile picture

Computational Cancer Pharmacologist | Postdoctoral Researcher at UNC Chapel Hill

Chapel Hill, NC
Joined February 2018
Photo by Dr. Amy Pomeroy (@AmyEPomeroy)Photo by Dr. Amy Pomeroy (@AmyEPomeroy)Photo by Dr. Amy Pomeroy (@AmyEPomeroy)Photo by Dr. Amy Pomeroy (@AmyEPomeroy)Photo by Dr. Amy Pomeroy (@AmyEPomeroy)Photo by Dr. Amy Pomeroy (@AmyEPomeroy)Photo by Dr. Amy Pomeroy (@AmyEPomeroy)Photo by Dr. Amy Pomeroy (@AmyEPomeroy)Photo by Dr. Amy Pomeroy (@AmyEPomeroy)Photo by Dr. Amy Pomeroy (@AmyEPomeroy)
Dr. Amy Pomeroy retweeted
It's postdoc appreciation week: I'm grateful for my lab's first postdoc @AmyEPomeroy - author of so many great papers on combination cancer pharmacology it needs a thread: Drug independence and the curability of cancer by combination chemotherapy doi.org/10.1016/j.trecan.202… 1/n
1
2
2
14
1,420
Dr. Amy Pomeroy retweeted
Spotlight: Antifragility in Cancer! @AmyEPomeroy & @ac_palmer wrote a Spotlight highlighting our recent mansucript on antifragile therapy dosing strategies in Cancer Research:
4
14
1
57
17,423
'Less is more' maintenance therapy in #MultipleMyeloma! Triplets→ASCT→3yr Len → D/C if MRD-neg (NGF+PET/CT-neg) Results: 3yr PFS ~93%, TFS ~75% *Treatment initiated for MRD resurgence Based on @bdermanmd 's MRD2STOP + this data: I'm comfortable stopping Len in standard-risk MRD-neg patients at 3yrs! However, with quad induction + MRD-neg 10^-6 by NGS, do we even need 3yrs of Len? As @End_myeloma reminds us, Len maintenance was built on the backbone of doublets! tinyurl.com/8thww4sz
4
21
90
4,923
Dr. Amy Pomeroy retweeted
A very well-written and thoughtful piece from Itai Yanai and Martin Lercher, with a nice visual showing how we “trim the tree” of the process, for publication. On a related note, I’d like to see more Math Onco papers show the discovery process within papers — e.g. the process of model selection!
1
4
23
1,262
i'm just a senior postdoc, standing in front of a career that i have worked really hard for, asking higher education in the united states to not completely implode in front of my eyes before i even get a chance to say the words 'my lab studies'
24
116
8
1,702
141,459
Dr. Amy Pomeroy retweeted
Congrats to Drs. Amy Pomeroy @AmyEPomeroy and Adam Palmer @ac_palmer! They published a mathematical model on multi-drug therapy with clinical implications that address tumor and patient heterogeneity in drug sensitivity! Read more through @BCD_AACR: aacrjournals.org/bloodcancer…
2
3
240
Dr. Amy Pomeroy retweeted
Congratulations @ac_palmer @AmyEPomeroy !!! Fantastic to see this work out!
1
3
107
First author Amy Pomeroy presents her recently published work in Blood Cancer Discovery: A model of curative combination therapy for lymphoma by @amyEpomeroy and @ac_palmer. Read the article: brnw.ch/21wRb8A
4
5
425
Dr. Amy Pomeroy @AmyEPomeroy is up next in our postdoc spotlight session telling us about their work on mechanistic modeling of combination therapy
1
3
6
210
Dr. Amy Pomeroy retweeted
New de-novo TCR design preprint from @DhuviKarthikey1 just dropped: TCR-TRANSLATE: Conditional Generation of Real Antigen Specific T-cell Receptor Sequences biorxiv.org/content/10.1101/…
1
19
1
96
9,250
📌 Prognostic utility of ctDNA detection in the monarchE trial of adjuvant abemaciclib plus endocrine therapy (ET) in HR+, HER2-, node-positive, high-risk early breast cancer (EBC). Great talk by @LoiSher @OncoAlert #ASCO24 #BreastCancer ✔️the largest study ➡️8% positive for ctDNA at baseline ➡️ ctDNA detection was highly prognostic of worse outcomes, particularly for patients who were persistently positive
1
15
1
26
6,848
Common Sense Oncology chapter is now live in ASCO Ed Book. Check it out. ascopubs.org/doi/pdf/10.1200… We also have a @csoncol session at #ASCO24 Monday morning 8AM!
2
27
1
76
22,300
Dr. Amy Pomeroy retweeted
In the ALINA trial of adjuvant treatment for patients with resected ALK-positive non–small-cell lung cancer, disease-free survival at 2 years was 93.6% with the ALK inhibitor alectinib & 63.7% with standard chemotherapy. Full results & Research Summary: nej.md/3VUzf3M
60
3
192
35,370
Dr. Amy Pomeroy retweeted
Positive OS readout of STARGLO: glofit-GemOx vs R-GemOx in transplant ineligible R/R DLBCL Will be exciting to see the full results @mike_dickinson1 – at Melbourne, Victoria
#Breaking: Today we announced our CD20xCD3 bispecific antibody in combination with chemotherapy met its primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell #lymphoma, or #DLBCL. Learn more: gene.com/media/press-release…
3
15
32
7,768
Dr. Amy Pomeroy retweeted
Exciting News! A new video capturing the mission of UNC's Computational Medicine Program. Catch the full video at KathASK Films on YouTube or simply click the following link for direct access: youtube.com/watch?v=YI8nHbmX… #PurvisLab #ComputationalMedicine #UNCSchoolOfMedicine
1
5
401
Dr. Amy Pomeroy retweeted
📣 For those attending #AACR24 and caught the eclipse, you can return your glasses at the @scientist_com booth 3553 for these to be donated for the kids in Latin America to enjoy the eclipse coming up this summer! @AACR @nysci
2
14
3
23
5,326
Dr. Amy Pomeroy retweeted
What to know about the latest computational approaches to precision medicine? Dr. Amy Pomeroy @AmyEPomeroy from the Palmer lab @ac_palmer will be presenting at #AACR24 TODAY from 4:05-4:20pm PST on their latest novel population tumor kinetics model! tinyurl.com/5am3am36
5
1
10
6,556
Dr. Amy Pomeroy retweeted
Lovely solar eclipse experience with 22,000 other scientists @aacr annual meeting! Everyone sharing their glasses #AACR24
4
12
1,223